Ameriprise
LAB icon

Ameriprise’s Standard BioTools LAB Stock Holding History

Ameriprise’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.2K Buy
+104,805
New +$99K ﹤0.01% 4030
2021
Q4 		– Sell
-10,910
Closed -$72K – 4011
2021
Q3 		$72K Sell
10,910
-400
-4% -$2.63K ﹤0.01% 3801
2021
Q2 		$70K Hold
11,310
– – ﹤0.01% 3846
2021
Q1 		$51K Sell
11,310
-90
-0.8% -$494 ﹤0.01% 3800
2020
Q4 		$69K Sell
11,400
-18,445
-62% -$121K ﹤0.01% 3709
2020
Q3 		$222K Buy
29,845
+19,240
+181% +$133K ﹤0.01% 3511
2020
Q2 		$42K Buy
+10,605
New +$36.9K ﹤0.01% 3623
2016
Q1 		– Sell
-106,861
Closed -$1.16M – 3818
2015
Q4 		$1.16M Buy
+106,861
New +$1.05M ﹤0.01% 2884
2014
Q4 		– Sell
-55
Closed -$1K – 4087
2014
Q3 		$1K Buy
55
+15
+38% +$422 ﹤0.01% 5555
2014
Q2 		$1K Sell
40
-16
-29% -$513 ﹤0.01% 5351
2014
Q1 		$2K Buy
56
+16
+40% +$704 ﹤0.01% 5054
2013
Q4 		$2K Sell
40
-1,585
-98% -$46.7K ﹤0.01% 4881
2013
Q3 		$36K Buy
1,625
+40
+3% +$786 ﹤0.01% 4010
2013
Q2 		$28K Buy
+1,585
New +$27.8K ﹤0.01% 4075

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Ameriprise's LAB Position: Q2 2026 in Review

Ameriprise opened a new position in Standard BioTools (LAB) in Q2 2026: 104,805 shares worth $86.2K. The stake represents ﹤0.01% of the portfolio and ranks #4030 among its holdings. This is a return to the name: Ameriprise previously reported a position in LAB as recently as Q3 2021.

Ameriprise first reported a position in LAB in Q2 2013 and has held it in 14 quarters since. The position peaked at $1.16M in Q4 2015. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Ameriprise held 104,805 shares of Standard BioTools worth $86.2K as of Q2 2026.
  • Standard BioTools was a new Ameriprise position in Q2 2026.
  • Standard BioTools made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #4030 holding.
  • Ameriprise first reported a position in Standard BioTools in Q2 2013 and has held it in 14 quarters since.
  • Ameriprise's Standard BioTools position peaked at $1.16M in Q4 2015.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.